Overview Dividends

(UFPT) UFP Technologies - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US9026731029

Foam, Packaging, Medical, Device, Components

UFPT EPS (Earnings per Share)

EPS Growth (3Y CAGR): -5.22%
EPS Trend (3Y Correlation): 51.2%

UFPT Revenue

Revenue Growth (3Y CAGR): 17.52%
Revenue Trend (3Y Correlation): 91.7%

Description: UFPT UFP Technologies

UFP Technologies Inc (NASDAQ:UFPT) is a US-based company operating in the Health Care Supplies sub-industry. The companys stock performance is characterized by a current price below its 20-day, 50-day, and 200-day simple moving averages, indicating a potential downtrend. The Average True Range (ATR) suggests a moderate level of volatility.

From a fundamental perspective, UFP Technologies has a market capitalization of approximately $1.59 billion, with a price-to-earnings ratio of 23.93 and a forward P/E of 22.17. The Return on Equity (RoE) stands at 18.93%, indicating a relatively strong ability to generate profits from shareholder equity. Key drivers of the companys financial performance likely include revenue growth, profit margins, and the overall demand for healthcare supplies.

To further analyze UFPTs potential, we can examine key performance indicators (KPIs) such as revenue growth rate, gross margin, operating margin, and debt-to-equity ratio. A high revenue growth rate and stable or expanding profit margins could indicate a strong competitive position and potential for future growth. Additionally, a reasonable debt-to-equity ratio would suggest that the company is managing its capital structure effectively.

Economic drivers that may impact UFPTs performance include overall healthcare spending, trends in medical device and supply demand, and the competitive landscape within the healthcare supplies industry. The companys ability to innovate, manage costs, and adapt to regulatory changes will also be crucial in determining its long-term success.

UFPT Stock Overview

Market Cap in USD	1,621m
Sub-Industry	Health Care Supplies
IPO / Inception	1993-12-16

UFPT Stock Ratings

Growth Rating	23.1%
Fundamental	79.9%
Dividend Rating	-
Return 12m vs S&P 500	-48.0%
Analyst Rating	3.75 of 5

UFPT Dividends

Currently no dividends paid

UFPT Growth Ratios

Growth Correlation 3m	-84.6%
Growth Correlation 12m	-75.5%
Growth Correlation 5y	95.2%
CAGR 5y	30.44%
CAGR/Max DD 3y	0.64
CAGR/Mean DD 3y	2.68
Sharpe Ratio 12m	-0.71
Alpha	-41.37
Beta	0.315
Volatility	42.09%
Current Volume	149.9k
Average Volume 20d	99.7k
Stop Loss	189.5 (-4.9%)
Signal	-0.11

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income (67.1m TTM) > 0 and > 6% of Revenue (6% = 35.3m TTM)

FCFTA 0.11 (>2.0%) and ΔFCFTA 1.24pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -0.22% (prev 26.44%; Δ -26.65pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 83.4m > Net Income 67.1m (YES >=105%, WARN >=100%)

Net Debt (148.7m) to EBITDA (112.6m) ratio: 1.32 <= 3.0 (WARN <= 3.5)

Current Ratio 0.99 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (7.78m) change vs 12m ago 0.39% (target <= -2.0% for YES)

Gross Margin 28.76% (prev 28.02%; Δ 0.74pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 111.4% (prev 98.83%; Δ 12.52pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 7.67 (EBITDA TTM 112.6m / Interest Expense TTM 12.3m) >= 6 (WARN >= 3)

Altman Z'' 4.38

(A) -0.00 = (Total Current Assets 185.0m - Total Current Liabilities 186.3m) / Total Assets 634.7m

(B) 0.54 = Retained Earnings (Balance) 340.9m / Total Assets 634.7m

(D) 1.37 = Book Value of Equity 340.9m / Total Liabilities 249.2m

Total Rating: 4.38 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 79.89

1. Piotroski 8.0pt = 3.0

2. FCF Yield 4.10% = 2.05

3. FCF Margin 12.32% = 3.08

4. Debt/Equity 0.42 = 2.41

5. Debt/Ebitda 1.45 = 1.04

6. ROIC - WACC 7.46% = 9.32

7. RoE 18.93% = 1.58

8. Rev. Trend 91.72% = 4.59

9. Rev. CAGR 17.52% = 2.19

10. EPS Trend 51.16% = 1.28

11. EPS CAGR -5.22% = -0.65

What is the price of UFPT shares?

As of September 15, 2025, the stock is trading at USD 199.32 with a total of 149,860 shares traded.
Over the past week, the price has changed by -3.14%, over one month by -11.02%, over three months by -16.09% and over the past year by -38.53%.

Is UFP Technologies a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, UFP Technologies (NASDAQ:UFPT) is currently (September 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 79.89 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of UFPT is around 198.66 USD . This means that UFPT is currently overvalued and has a potential downside of -0.33%.

Is UFPT a buy, sell or hold?

UFP Technologies has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold UFPT.

Strong Buy: 1
Buy: 1
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the UFPT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	329.5	65.3%
Analysts Target Price	329.5	65.3%
ValueRay Target Price	217.8	9.3%

Last update: 2025-09-01 05:05

UFPT Fundamental Data Overview

Market Cap USD = 1.62b (1.62b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 14.9m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 24.3805
P/E Forward = 22.1729
P/S = 2.7535
P/B = 4.2039
Beta = 1.136
Revenue TTM = 588.6m USD
EBIT TTM = 94.5m USD
EBITDA TTM = 112.6m USD
Long Term Debt = 151.1m USD (from longTermDebt, last quarter)
Short Term Debt = 12.5m USD (from shortTermDebt, last quarter)
Debt = 163.6m USD (Calculated: Short Term 12.5m + Long Term 151.1m)
Net Debt = 148.7m USD (from netDebt column, last quarter)
Enterprise Value = 1.77b USD (1.62b + Debt 163.6m - CCE 14.9m)
Interest Coverage Ratio = 7.67 (Ebit TTM 94.5m / Interest Expense TTM 12.3m)
FCF Yield = 4.10% (FCF TTM 72.5m / Enterprise Value 1.77b)
FCF Margin = 12.32% (FCF TTM 72.5m / Revenue TTM 588.6m)
Net Margin = 11.40% (Net Income TTM 67.1m / Revenue TTM 588.6m)
Gross Margin = 28.76% ((Revenue TTM 588.6m - Cost of Revenue TTM 419.3m) / Revenue TTM)
Tobins Q-Ratio = 5.19 (Enterprise Value 1.77b / Book Value Of Equity 340.9m)
Interest Expense / Debt = 1.63% (Interest Expense 2.67m / Debt 163.6m)
Taxrate = 19.23% (14.0m / 73.0m)
NOPAT = 76.4m (EBIT 94.5m * (1 - 19.23%))
Current Ratio = 0.99 (Total Current Assets 185.0m / Total Current Liabilities 186.3m)
Debt / Equity = 0.42 (Debt 163.6m / last Quarter total Stockholder Equity 385.5m)
Debt / EBITDA = 1.45 (Net Debt 148.7m / EBITDA 112.6m)
Debt / FCF = 2.26 (Debt 163.6m / FCF TTM 72.5m)
Total Stockholder Equity = 354.5m (last 4 quarters mean)
RoA = 10.57% (Net Income 67.1m, Total Assets 634.7m )
RoE = 18.93% (Net Income TTM 67.1m / Total Stockholder Equity 354.5m)
RoCE = 18.70% (Ebit 94.5m / (Equity 354.5m + L.T.Debt 151.1m))
RoIC = 14.10% (NOPAT 76.4m / Invested Capital 541.5m)
WACC = 6.64% (E(1.62b)/V(1.78b) * Re(7.18%)) + (D(163.6m)/V(1.78b) * Rd(1.63%) * (1-Tc(0.19)))
Shares Correlation 3-Years: 90.91 | Cagr: 0.17%
Discount Rate = 7.18% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈60.7m ; Y1≈74.9m ; Y5≈127.9m
Fair Price DCF = 282.0 (DCF Value 2.17b / Shares Outstanding 7.71m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 91.72 | Revenue CAGR: 17.52%
Rev Growth-of-Growth: 19.94
EPS Correlation: 51.16 | EPS CAGR: -5.22%
EPS Growth-of-Growth: 26.46

Additional Sources for UFPT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle